Muscle Relaxants During Robotic Surgery for Prostate Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic prostate surgery with deep neuromuscular blockade (NMB), compared with moderate NMB.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are taking Toremifene, suboxone, or succinylcholine, you cannot participate.
What data supports the effectiveness of the drug Rocuronium for use during robotic surgery for prostate cancer?
Rocuronium is a muscle relaxant that works quickly and is effective in creating good conditions for intubation (inserting a tube into the windpipe) during surgery, as shown in studies with doses similar to those used in your trial. It has been found to be a useful alternative to other muscle relaxants for rapid procedures, which may support its use in robotic surgery for prostate cancer.12345
Is rocuronium generally safe for use in humans?
How does the drug rocuronium differ from other treatments for prostate cancer surgery?
Rocuronium is a muscle relaxant used during surgery that has a rapid onset and intermediate duration, making it suitable for quick and effective muscle relaxation during robotic prostate cancer surgery. This differs from other treatments as it specifically aids in providing optimal surgical conditions by relaxing muscles, which is crucial for the precision required in robotic procedures.1291011
Research Team
Elizabeth Rieth, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for men under 80 years old undergoing elective robotic prostate surgery without neuromuscular diseases, severe renal impairment, or a history of certain abdominal surgeries. They must not have allergies to specific anesthetics and pain medications, and cannot be on drugs like suboxone or Toremifene.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo robotic prostate surgery with either deep or moderate neuromuscular blockade
Follow-up
Participants are monitored for intra-abdominal pressure and postoperative pain for up to 1 year
Treatment Details
Interventions
- Rocuronium 0.3mg/kg/hr
- Rocuronium 1.5mg/kg/hr
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor